BTIG Reaffirms Their Hold Rating on Tri Pointe (TPH)
BTIG analyst Carl Reichardt maintained a Hold rating on Tri Pointe (TPH – Research Report) on April 25. The company's shares closed last Friday at $30.33.
Stay Ahead of the Market:
Discover outperforming stocks and invest smarter with Top Smart Score Stocks.
Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener.
Reichardt covers the Consumer Cyclical sector, focusing on stocks such as PulteGroup, Taylor Morrison, and DR Horton. According to TipRanks, Reichardt has an average return of 14.0% and a 55.38% success rate on recommended stocks.
In addition to BTIG, Tri Pointe also received a Hold from RBC Capital's Michael Dahl in a report issued on April 24. However, on the same day, Evercore ISI maintained a Buy rating on Tri Pointe (NYSE: TPH).
TPH market cap is currently $2.75B and has a P/E ratio of 6.75.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
TSMC CEO Tells Trump $100 Billion US Chip Expansion Will 'Take Time' Amid Tariff Pressures, Surging AI Demand
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Taiwan Semiconductor Manufacturing Company Limited (NYSE:TSM) CEO C.C. Wei revealed during Tuesday's shareholder meeting that he informed President Donald Trump that establishing a proposed $100 billion U.S. manufacturing venture will 'take time,' beyond the anticipated timeline. What Happened: Wei disclosed that TSMC has maintained ongoing dialogue with the U.S. Commerce Department regarding Trump's semiconductor tariffs since their implementation, reported Baha Breaking News. Don't Miss: Start investing with eToro's CopyTrader — mirror top-performing traders with no management fees, and receive a $10 bonus when you deposit $100 today. Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — you can become an investor for $0.80 per share today. The CEO expressed concerns that higher duties would elevate TSMC's U.S. production costs, though he emphasized that tariff policies remain 'ultimately a matter between governments, not between a government and a company.' Despite tariff headwinds, Wei assured investors that artificial intelligence chip demand continues to substantially outpace supply capabilities. Why It Matters: The CEO explained that while tariffs don't directly impact TSMC as an exporter, they create indirect pressure through higher import costs for customers. 'Tariffs can lead to slightly higher prices and when prices go up, demand may go down,' Wei noted. TSMC's cautious stance on U.S. expansion comes as the chipmaker weighs the massive $100 billion investment over four years to build advanced manufacturing facilities stateside. The company has already committed over $65 billion to Arizona fabrication plants for advanced chip production. Read Next: Nancy Pelosi Invested $5 Million In An AI Company Last Year — Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000. Invest Where It Hurts — And Help Millions Heal: Invest in Cytonics and help disrupt a $390B Big Pharma stronghold. Photo courtesy: Jack Hong / This article TSMC CEO Tells Trump $100 Billion US Chip Expansion Will 'Take Time' Amid Tariff Pressures, Surging AI Demand originally appeared on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
33 minutes ago
- Business Insider
PROCEPT BioRobotics (PRCT) Gets a Buy from TD Cowen
In a report released yesterday, Josh Jennings from TD Cowen reiterated a Buy rating on PROCEPT BioRobotics (PRCT – Research Report). The company's shares closed yesterday at $65.05. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Jennings covers the Healthcare sector, focusing on stocks such as Abbott Laboratories, Medtronic, and Establishment Labs Holdings. According to TipRanks, Jennings has an average return of 4.6% and a 52.11% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for PROCEPT BioRobotics with a $80.20 average price target. PRCT market cap is currently $3.32B and has a P/E ratio of -36.24. Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PRCT in relation to earlier this year. Most recently, in March 2025, Reza Zadno, the President & CEO of PRCT sold 5,475.00 shares for a total of $312,403.50.
Business Insider
an hour ago
- Business Insider
Stifel Nicolaus Keeps Their Buy Rating on Kymera Therapeutics (KYMR)
analyst Alex Thompson CFA maintained a Buy rating on Kymera Therapeutics (KYMR – Research Report) yesterday and set a price target of $68.00. The company's shares closed yesterday at $47.66. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Thompson CFA covers the Healthcare sector, focusing on stocks such as Kymera Therapeutics, Oruka Therapeutics, and Travere Therapeutics. According to TipRanks, Thompson CFA has an average return of -2.8% and a 45.45% success rate on recommended stocks. In addition to Stifel Nicolaus, Kymera Therapeutics also received a Buy from UBS's Eliana Merle in a report issued on June 3. However, on May 30, Bank of America Securities maintained a Hold rating on Kymera Therapeutics (NASDAQ: KYMR). The company has a one-year high of $53.27 and a one-year low of $19.45. Currently, Kymera Therapeutics has an average volume of 856.8K.
